NEWS
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide influenced treatment decisions in over 90% of cases
80% sensitivity in detecting tumor cells compared to 29% for CSF cytology
Identified actionable mutations, influencing 24% of therapeutic selections
High specificity with no false positives
These results suggest CNSide's potential for earlier LM diagnosis and improved patient management.
CNSide influenced treatment decisions in over 90% of cases
80% sensitivity in detecting tumor cells compared to 29% for CSF cytology
Identified actionable mutations, influencing 24% of therapeutic selections
High specificity with no false positives
These results suggest CNSide's potential for earlier LM diagnosis and improved patient management.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1662Followers
91Following
13KVisitors
Follow